MYNEO THERAPEUTICS

A little history

myNEO was founded in 2018 by leading biotech entrepreneurs combining expertise from different academic institutions. Cedric Bogaert, Jan Van Den Berghe, and Wim van Criekinge have since then expanded the team with established domain in antigen discovery experts as well as ambitious talent to further grow the company's innovation and developments.

myNEO offices

To date, myNEO has achieved several pivotal milestones in realizing its vision. These include:

  • Development of state-of-the-art antigen prediction algorithms
  • Discovery of novel, dark antigen targets called camyotopes
  • (Co-)development of novel immunotherapeutics products via strategic collaborations or in-house, leading to 3 separate programs executing successful IND/CTA filings in 2025
  • The publication of high-impact scientific papers
  • ISO and regulatory approval for clinical use of technology
  • Securing valuable intellectual property with multiple patents
  • Receiving several prestigious awards (Most Disruptive Innovator, Forbes 30under30, Rising Star Fast50)
Jens De Ceukeleire

Jens De Ceukeleire

Principal data scientist

Jens holds a Master's in Biochemistry and Biotechnology from Ghent University, specializing in bioinformatics. During his several years at Agilent Technologies, he developed and optimized advanced NGS pipelines and built applications for clinical genomics platforms, supporting healthcare professionals through cutting-edge variant calling.

At myNEO, Jens's experience in performance optimization and software engineering ensures that our algorithms deliver results with the fastest turnaround possible. Thanks to his work, the ImmunoEngine can process a whole-genome sequencing tumor-derived dataset in 3 to 5 days. Jens was also instrumental in making the myRNA tool suite operate in tractable time.

View LinkedIn profile